Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
On 6ix: 6ix.com/news/ultragenyx-announces-positive-top-line-results-phase-3-study-dtx401-gene-therapy
Watch Ultragenyx Pharmaceutical's latest callUltragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Ultragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings CallUltragenyx Pharmaceutical Inc. on 6ix
Story so far
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
Earlier from Ultragenyx Pharmaceutical
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Later from Ultragenyx Pharmaceutical
- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
- Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Follow Ultragenyx Pharmaceutical into a list and get an email when it puts out news.
Follow Ultragenyx Pharmaceutical